Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Share News (EVG)

  • There is currently no data for EVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Broking boss makes £2.6m profit

Mon, 02nd Nov 2009 16:30

Evolution chief executive Alex Snow has sold £5.2m of shares after being awarded 4.59m shares from two company option schemes after the vesting conditions for the shares were met. The Evolution Group Plc 2000 Executive Share Option Scheme issued 3.09m shares to Snow, Of these, 2.026m did not have any performance criteria, while the award of the rest was based on share price performance. These shares were acquired at 58.67p a share. The total cost was £1.81m. The other 1.5m shares were issued under the Evolution Group Plc 2001 Executive Share Option Scheme - following the achievement of share price performance criteria - and they cost 52.3p each. The total cost was £785,000. That means that Snow made a £2.6m profit on the share sales, which were at 163p a share. The share price is the highest it has been for more than three years. He retains 1.4m of the shares that he was awarded. This still leaves Snow with a higher percentage of the company. He owns 5.6m shares, which is equivalent to 2.42% of Evolution. Snow has taken up all the shares he had under option at the time of the 2008 annual report. Last week, the broker announced that its 2009 profits would be better than expected. Corporate activity has increased in the second half of the year. Funds under management have grown to £5bn at the end of September 2009. In April, Snow raised nearly £927,000 by selling shares at 114p each. That followed the exercise of options over 2m shares at 1p each - a total cost of £20,000. Snow said that the sale proceeds paid for the options and associated tax costs. That means that Snow has made more than £3.5m profit from share sales this year, while retaining 2.57m shares he has been awarded. Top Director BuysAccess Intelligence (ACC) Director name: Mr David LoweAmount purchased: 961,111 @ 4.70p Value: £45,172CLS Holdings (CLI) Director name: Mr Sten A MortstedtAmount purchased: 7,940 @ 443.00p Value: £35,174Jetion Solar Holdings (JHL) Director name: Mr Raymond WongAmount purchased: 30,000 @ 64.50p Value: £19,350Top Director SellsEvolution Group (EVG) Director name: Mr Alex SnowAmount sold: 3,191,565 @ 163.00p Value: £5,202,251Diageo (DGE) Director name: Mr Paul S WalshAmount sold: 99,000 @ 1,000.00p Value: £990,000
More News
23 Nov 2020 17:37

IN BRIEF: Evgen Pharma Doses First Patient In Lead Candidate Trial

IN BRIEF: Evgen Pharma Doses First Patient In Lead Candidate Trial

Read more
23 Nov 2020 12:22

Evgen doses first patients in 'STAR' respiratory trial

(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced on Monday that the first patient had now been enrolled and dosed in the 'STAR' trial of its 'SFX-01' treatment for acute respiratory infections.

Read more
11 Nov 2020 15:53

IN BRIEF: Evgen Pharma About To Begin SFX-01 Trial Recruitment

IN BRIEF: Evgen Pharma About To Begin SFX-01 Trial Recruitment

Read more
23 Oct 2020 11:49

Evgen gets full approval for SFX-01 trial in Covid-19 patients

(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced on Friday that all necessary regulatory approvals had now been received for the 'STAR' trial of SFX-01 treatment for Acute Respiratory Infections.

Read more
23 Oct 2020 11:31

Shares In Evgen Pharma Rise On Approval For SFX-01 Trial

Shares In Evgen Pharma Rise On Approval For SFX-01 Trial

Read more
23 Oct 2020 10:46

UK WINNERS & LOSERS SUMMARY: Barclays Lifts FTSE's Lenders

UK WINNERS & LOSERS SUMMARY: Barclays Lifts FTSE's Lenders

Read more
24 Sep 2020 18:12

UK EXECUTIVE CHANGE SUMMARY: Carr's Names Pelham To Replace CEO Davies

UK EXECUTIVE CHANGE SUMMARY: Carr's Names Pelham To Replace CEO Davies

Read more
15 Sep 2020 22:08

UK TRADING UPDATE SUMMARY: Mortgage Advice Bureau Launches Later Life

UK TRADING UPDATE SUMMARY: Mortgage Advice Bureau Launches Later Life

Read more
15 Sep 2020 08:41

Evgen Pharma licences technology to Juvenescence

(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced the licensing of its sulforaphane stabilisation technology in a number of non-pharmaceutical applications to Juvenescence on Tuesday.

Read more
9 Jul 2020 16:16

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
17 Jun 2020 12:01

Evgen's 'SFX-01' to be tested with Covid-19 patients

(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced its participation in the recently-notified funding initiative for Covid-19 clinical trials by the medical research charity LifeArc on Wednesday.

Read more
17 Jun 2020 10:42

Evgen Pharma Says SFX-01 To Be Evaluated In Covid-19 Trial

Evgen Pharma Says SFX-01 To Be Evaluated In Covid-19 Trial

Read more
15 Jun 2020 11:09

UK WINNERS & LOSERS SUMMARY: Bunzl Rises As It Sees Strong First Half

UK WINNERS & LOSERS SUMMARY: Bunzl Rises As It Sees Strong First Half

Read more
15 Jun 2020 10:24

Evgen Pharma Loss Slightly Wider On Expenses And Compensation

Evgen Pharma Loss Slightly Wider On Expenses And Compensation

Read more
15 Jun 2020 09:51

Losses widen as Evgen Pharma develops SFX-01

(Sharecast News) - Clinical-stage drug development company Evgen Pharma reported a slight widening of its post-tax loss in its final results on Monday, to £2.7m, from £2.6m in the prior year.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.